Login
Companies $INAB
$0.75 -$0.07 (8.05%) After hours
IN8BIO, INC. logo

IN8BIO, INC.

in8bio.com

What Do They Do?

Develops therapies using gamma-delta immune cells and immune-cell engagers for cancer and autoimmune diseases.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −19% (Loss)
vs −$3.9M in Q3 FY2025

Expanded into T-cell engagers The older report described gamma-delta cell product candidates for solid and liquid tumors. The latest report also describes T-cell engagers for cancer and autoimmune diseases.

Who Do They Compete With?

Competes with Acepodia USA, Adicet Bio, American Gene Technologies International, Century Therapeutics, CytoMed Therapeutics, Editas Medicine, Enochian BioSciences, Eureka Therapeutics, Expression Therapeutics, Immatics Biotechnologies, Johnson & Johnson, Kiromic Biopharma, OverT Bio, PersonGen BioTherapeutics (Suzhou), PhosphoGam, Regeneron Pharmaceuticals, Sandhill Therapeutics, Senti Biosciences, Shattuck Labs, and Xoma Royalty

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support